This study systematically compared the efficacy and safety of different Chinese medicine injections when used in tandem with Western medicine treatments for stable angina pectoris. PubMed, Cochrane Library, EMBASE, Web of Science, CNKI, Wanfang, VIP, and SinoMed databases were reviewed for randomized controlled trials (RCTs) examining the synergy of Chinese medicine injections and conventional Western medicine in the treatment of stable angina pectoris, spanning from their inception to July 8, 2022. IgE-mediated allergic inflammation Literature screening, data extraction, and bias risk evaluation of the included studies were carried out by two independently working researchers. Network Meta-analysis was performed using Stata 151. In this study, 52 randomized controlled trials, encompassing 4,828 patients, were scrutinized, each patient receiving treatment with a group of 9 Chinese medicine injections (Danhong Injection, Salvia Miltiorrhiza Polyphenol Hydrochloride Injection, Tanshinone Sodium A Sulfonate Injection, Salvia Miltiorrhiza Ligustrazine Injection, Dazhu Hongjingtian Injection, Puerarin Injection, Safflower Yellow Pigment Injection, Shenmai Injection, and Xuesaitong Injection). A network meta-analysis of available data highlighted(1)the potential for increasing efficacy of angina pectoris treatment. The cumulative ranking curve (SUCRA) surface demonstrated a hierarchical structure of treatments mirroring conventional Western medicine, starting with Salvia Miltiorrhiza Ligustrazine Injection and culminating in Dazhu Hongjingtian Injection, encompassing Tanshinone Sodium A Sulfonate Injection, Danhong Injection, and other listed injections. SUCRA's strategy, aligning with established Western medicine, consisted of a sequential administration of Salvia Miltiorrhiza Ligustrazine Injection, Puerarin Injection, Danhong Injection, Salvia Miltiorrhiza Polyphenol Hydrochloride Injection, Shenmai Injection, Xuesaitong Injection, Safflower Yellow Pigment Injection, Tanshinone Sodium A Sulfonate Injection, and Dazhu Hongjingtian Injection; this regimen was intended to elevate high-density lipoprotein cholesterol (HDL-C). In accordance with standard Western medical procedures, SUCRA's treatment plan involved administering Danhong Injection, followed by Shenmai Injection, Safflower Yellow Pigment Injection, Xuesaitong Injection, Tanshinone Sodium A Sulfonate Injection, and culminating with Dazhu Hongjingtian Injection; this regimen was established with the goal of lowering low-density lipoprotein cholesterol (LDL-C). SUCRA's treatment plan, aligning with the protocols of conventional Western medicine, comprised the administration of Safflower Yellow Pigment Injection, Danhong Injection, Shenmai Injection, Tanshinone Sodium A Sulfonate Injection, Dazhu Hongjingtian Injection, and Xuesaitong Injection; (5) Safety procedures were rigorously adhered to. Incorporating Chinese medicine injections into conventional Western medicine regimens resulted in a lower overall incidence of adverse reactions in comparison to the control group. The combination of Chinese medicine injections and conventional Western medicine exhibited an improvement in the therapeutic outcome for stable angina pectoris, while maintaining a high degree of safety, as evidenced by current research. see more The preceding conclusion, constrained by the quantity and quality of the reviewed studies, demands confirmation through subsequent high-quality research endeavors.

In rat plasma and urine, the UPLC-MS/MS method was established for the quantitative analysis of acetyl-11-keto-beta-boswellic acid (AKBA) and beta-boswellic acid (-BA), the chief active components of Olibanum and Myrrha extracts within the Xihuang Formula. Pharmacokinetic analyses of AKBA and -BA in rats were performed to evaluate the impact of compatibility, contrasting the pharmacokinetic responses in healthy rats with those exhibiting precancerous breast lesions. The study's findings suggest a significant enhancement in the AUC (0-t) and AUC (0-) values for -BA (P<0.005 or P<0.001), contrasted with the RM-NH and RM-SH groups after compatibility. This improvement was coupled with a significant decrease in T (max) (P<0.005 or P<0.001) and a marked increase in C (max) (P<0.001). The parallel trends of AKBA and -BA were evident. The Xihuang Formula normal group demonstrated a decrease in T (max) (P<0.005) relative to the RM-SH group, accompanied by an increase in C (max) (P<0.001) and an increase in absorption rate. Compatibility-related urinary excretion data showed a downward pattern in -BA and AKBA excretion rates and total urinary excretion, despite lacking statistical significance. The breast precancerous lesion group displayed a statistically significant upswing in AUC (0-t) and AUC (0-) for -BA in comparison to the normal Xihuang Formula group (P<0.005). This was coupled with a significant rise in T (max) (P<0.005) and a corresponding decrease in the clearance rate in this specific group. An increasing pattern was observed in the area under the curve (AUC) from zero to time t (AUC(0-t)) and from zero to negative infinity (AUC(0-)) for AKBA, coupled with a prolonged in vivo retention time and a diminished clearance rate. However, no significant difference compared to the normal group was detected. The cumulative urinary excretion and urinary excretion rate of -BA and AKBA decreased significantly in pathological situations. This demonstrates that pathological conditions can alter the in vivo fate of -BA and AKBA, resulting in lower excretion of the prototype drugs. This highlights pharmacokinetic variations in pathological versus normal physiological states. Employing UPLC-MS/MS, this study established a method appropriate for in vivo pharmacokinetic analysis of both -BA and AKBA. The present study provided a crucial basis for the creation of innovative dosage forms derived from Xihuang Formula.

As living standards improve and work styles change, abnormal glucose and lipid metabolism becomes more prevalent in modern society. Clinical markers linked to these conditions frequently show improvement when adopting a modified lifestyle and/or using hypoglycemic and lipid-lowering medications; however, there presently exist no medicinal treatments tailored to address dysfunctions in glucose and lipid metabolism. Protein 6, a binding protein for the Hepatitis C virus core protein (HCBP6), is a newly identified regulator of triglyceride and cholesterol levels, impacting abnormal glucose and lipid metabolism based on fluctuations within the body. Numerous studies have reported the notable upregulation of HCBP6 expression by ginsenoside Rh2, contrasting with the limited research on Chinese herbal medicine's effects on HCBP6. The three-dimensional structure of HCBP6 has yet to be determined, which is a significant impediment to the rapid identification of active compounds that interact with it. In this study, the total saponins from eight frequently utilized Chinese herbal remedies for regulating glucose and lipid metabolism were selected to investigate their effects on the expression of the HCBP6 gene. Computational prediction of HCBP6's three-dimensional structure was performed, and molecular docking was subsequently conducted with saponins extracted from eight Chinese herbal medicines, with the aim of quickly identifying potential active components. The results demonstrated that total saponins collectively had a tendency towards enhancing the expression of both HCBP6 mRNA and protein; while gypenosides exhibited the most effective upregulation of HCBP6 mRNA, ginsenosides demonstrated the most profound upregulation of HCBP6 protein levels. SAVES evaluation, following Robetta's protein structure prediction, yielded reliable protein structures. cancer precision medicine Collected from the website and literature, the saponins were also docked with the predicted protein; the saponin components exhibited strong binding activity with the HCBP6 protein. The forthcoming study is expected to formulate creative methodologies and concepts for the generation of new pharmaceuticals using Chinese herbal medicine to manage glucose and lipid metabolism.

By administering Sijunzi Decoction via gavage to rats, the study used UPLC-Q-TOF-MS/MS to identify the components that enter the bloodstream. Network pharmacology, molecular docking, and experimental validation were then utilized to investigate the mechanistic underpinnings of Sijunzi Decoction's Alzheimer's disease treatment effects. Mass spectra, coupled with data from the literature and databases, allowed for the determination of the components of Sijunzi Decoction that contribute to blood replenishment. To determine potential therapeutic targets in the context of Alzheimer's disease, the previously mentioned blood-borne treatment components were cross-checked with PharmMapper, OMIM, DisGeNET, GeneCards, and TTD databases. STRING was implemented in the subsequent phase to build a protein-protein interaction network (PPI). DAVID was tasked with the execution of Gene Ontology (GO) annotation and the elucidation of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Visual analysis was performed using Cytoscape version 39.0. Molecular docking of the blood-entering components against potential targets was performed using AutoDock Vina and PyMOL. Following KEGG pathway analysis, the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway was selected for subsequent validation using animal experiments. The results indicated that 17 blood-borne components were identified within the serum samples subsequent to administration. Sijunzi Decoction, employed in the treatment of Alzheimer's disease, contains, among its essential components, poricoic acid B, liquiritigenin, atractylenolide, atractylenolide, ginsenoside Rb1, and glycyrrhizic acid. Sijunzi Decoction's impact on Alzheimer's disease is notably linked to its effect on the molecular targets HSP90AA1, PPARA, SRC, AR, and ESR1. Analysis of molecular docking data indicated a high degree of binding affinity between the components and their target molecules. Hence, our hypothesis centers on the potential link between Sijunzi Decoction's therapeutic action against Alzheimer's disease and the PI3K/Akt, cancer treatment, and mitogen-activated protein kinase (MAPK) signaling pathways.